IE
SPRO icon

Israel Englander’s Spero Therapeutics SPRO Stock Holding History

Israel Englander’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.6K Buy
+19,298
New +$50.5K ﹤0.01% 5636
2026
Q1 		– Sell
-24,107
Closed -$56.2K – 6340
2025
Q4 		$56.2K Buy
+24,107
New +$56K ﹤0.01% 5721
2024
Q4 		– Sell
-32,172
Closed -$43.1K – 6436
2024
Q3 		$43.1K Sell
32,172
-66,346
-67% -$89K ﹤0.01% 5703
2024
Q2 		$128K Sell
98,518
-49,354
-33% -$74.4K ﹤0.01% 5259
2024
Q1 		$254K Sell
147,872
-985
-0.7% -$1.54K ﹤0.01% 5229
2023
Q4 		$219K Buy
148,857
+29,163
+24% +$34.8K ﹤0.01% 5138
2023
Q3 		$145K Sell
119,694
-254,156
-68% -$352K ﹤0.01% 5230
2023
Q2 		$542K Sell
373,850
-120,691
-24% -$207K ﹤0.01% 4483
2023
Q1 		$717K Sell
494,541
-381,857
-44% -$639K ﹤0.01% 4369
2022
Q4 		$1.52M Buy
876,398
+188,002
+27% +$351K ﹤0.01% 3796
2022
Q3 		$1.38M Buy
688,396
+373,753
+119% +$372K ﹤0.01% 4065
2022
Q2 		$233K Buy
314,643
+253,382
+414% +$737K ﹤0.01% 5552
2022
Q1 		$533K Buy
+61,261
New +$628K ﹤0.01% 5078
2021
Q2 		– Sell
-12,635
Closed -$186K – 7069
2021
Q1 		$186K Sell
12,635
-45,427
-78% -$799K ﹤0.01% 5517
2020
Q4 		$1.13M Sell
58,062
-72,512
-56% -$1.13M ﹤0.01% 3660
2020
Q3 		$1.46K Buy
130,574
+94,581
+263% +$1.12M ﹤0.01% 2851
2020
Q2 		$487K Buy
35,993
+21,938
+156% +$246K ﹤0.01% 3419
2020
Q1 		$114K Buy
14,055
+1,373
+11% +$12.1K ﹤0.01% 3532
2019
Q4 		$122K Buy
+12,682
New +$137K ﹤0.01% 3988
2018
Q2 		– Sell
-11,415
Closed -$163K – 4144
2018
Q1 		$163K Buy
+11,415
New +$138K ﹤0.01% 3408

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's SPRO Position: Q2 2026 in Review

Israel Englander opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 19,298 shares worth $42.6K. The stake represents ﹤0.01% of the portfolio and ranks #5636 among its holdings. This is a return to the name: Israel Englander previously reported a position in SPRO as recently as Q4 2025.

Israel Englander first reported a position in SPRO in Q1 2018 and has held it in 20 quarters since. The position peaked at $1.52M in Q4 2022. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Israel Englander held 19,298 shares of Spero Therapeutics worth $42.6K as of Q2 2026.
  • Spero Therapeutics was a new Israel Englander position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5636 holding.
  • Israel Englander first reported a position in Spero Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Israel Englander's Spero Therapeutics position peaked at $1.52M in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.